Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
6791872
Reference Type
Journal Article
Title
Taurine Supplementation Lowers Blood Pressure and Improves Vascular Function in Prehypertension Randomized, Double-Blind, Placebo-Controlled Study
Author(s)
Sun, Q; Chen, J; Zeng, X; Zhao, Z; He, H; Liu, D; Zhu, Z; Wang, Bin; Li, Y; Sun, F; Li, P; Xia, W; Zhou, X; Li, Q; Wang, X; ,
Year
2016
Is Peer Reviewed?
Yes
Journal
Hypertension
ISSN:
0194-911X
EISSN:
1524-4563
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Location
PHILADELPHIA
Page Numbers
541-549
PMID
26781281
DOI
10.1161/HYPERTENSIONAHA.115.06624
Web of Science Id
WOS:000369755200016
Abstract
Taurine, the most abundant, semiessential, sulfur-containing amino acid, is well known to lower blood pressure (BP) in hypertensive animal models. However, no rigorous clinical trial has validated whether this beneficial effect of taurine occurs in human hypertension or prehypertension, a key stage in the development of hypertension. In this randomized, double-blind, placebo-controlled study, we assessed the effects of taurine intervention on BP and vascular function in prehypertension. We randomly assigned 120 eligible prehypertensive individuals to receive either taurine supplementation (1.6 g per day) or a placebo for 12 weeks. Taurine supplementation significantly decreased the clinic and 24-hour ambulatory BPs, especially in those with high-normal BP. Mean clinic systolic BP reduction for taurine/placebo was 7.2/2.6 mmHg, and diastolic BP was 4.7/1.3 mmHg. Mean ambulatory systolic BP reduction for taurine/placebo was 3.8/0.3 mmHg, and diastolic BP was 3.5/0.6 mmHg. In addition, taurine supplementation significantly improved endothelium-dependent and endothelium-independent vasodilation and increased plasma H2S and taurine concentrations. Furthermore, changes in BP were negatively correlated with both the plasma H2S and taurine levels in taurine-treated prehypertensive individuals. To further elucidate the hypotensive mechanism, experimental studies were performed both in vivo and in vitro. The results showed that taurine treatment upregulated the expression of hydrogen sulfide-synthesizing enzymes and reduced agonist-induced vascular reactivity through the inhibition of transient receptor potential channel subtype 3-mediated calcium influx in human and mouse mesenteric arteries. In conclusion, the antihypertensive effect of chronic taurine supplementation shows promise in the treatment of prehypertension through improvement of vascular function.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity